The recent release of drugs such
as sofosbuvir has marked the first successful and nontoxic treatments for hepatitis C — treatments which came directly from the work of Bartenschlager, Rice, and Sofia.
Not exact matches
Taylor's team of researchers examined Medicaid policies for hepatitis C virus treatment using
sofosbuvir, more commonly known
as Solvadi, and found that most should change policy to improve access to the treatment.
In a more advanced trial, 12 weeks of
sofosbuvir plus ribavirin yielded the same results
as 24 weeks of interferon plus ribavirin: 67 percent of patients had no evidence of the virus in their blood (although side effects such
as fever and depression were fewer among patients who did not receive interferon).
Using
sofosbuvir - ledipasvir, which is sold
as Harvoni, and is one several new drugs for hepatitis C, researchers compared the costs of treating patients at all stages of fibrosis, zero through four, with the cost of waiting until stages three or four, which is when some patients are usually treated.
As part of a compassionate use program, 104 post-liver transplant patients with recurring HCV who had exhausted all treatment options and had poor clinical prognoses, received
sofosbuvir (SOF) and ribavirin (RBV) with pegylated interferon (PEG) included at the physicians» discretion for up to 48 weeks.
Today, with just 12 weeks of treatment with drug combinations that use Sofia's drug,
sofosbuvir (Sovaldi ®)
as the backbone of Harvoni ®, almost all those treated are cured.